Company intelligence / Profile preview

Nanjing Olimus Pharmaceutical Technology

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Olimus Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on targeting key signaling pathways in oncology, such as the PI3K/mTOR and MAPK pathways, to treat various solid tumors and hematological malignancies. Olimus leverages its internal R&D capabilities to advance a pipeline of proprietary drug candidates through early-stage clinical trials. The firm aims to address significant unmet medical needs in the Chinese and global markets through precision medicine and high-efficiency drug design.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Olimus Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Olimus Pharmaceutical Technology.

Explore the full profile